GSWM
ANIP icon

Golden State Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Golden State Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$308 – 1626
2026
Q1 		$308 Hold
4
– – ﹤0.01% 1535
2025
Q4 		$316 Hold
4
– – ﹤0.01% 1611
2025
Q3 		$366 Buy
+4
New +$326 ﹤0.01% 1592

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Wealth Management's ANIP Position: Q2 2026 in Review

Golden State Wealth Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 4 shares — an estimated $308 sold.

Golden State Wealth Management first reported a position in ANIP in Q3 2025 and held it in 3 quarters. The position peaked at $366 in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Golden State Wealth Management reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 4 ANI Pharmaceuticals shares in Q2 2026, an estimated $308.
  • Golden State Wealth Management first reported a position in ANI Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Golden State Wealth Management's ANI Pharmaceuticals position peaked at $366 in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.